2014 Joint ACTRIMS-ECTRIMS Meeting
The 2014 Joint ACTRIMS-ECTRIMS Meeting will feature "a premiere program covering a wide range of tracks and presentation topics including genetics, pathogenesis, factors that determine MS susceptibility and treatment strategies, to study outcomes and research advances, to the latest in regeneration and rehabilitation."
A series of nurse-led interventions and patient education, along with titrated drug initiation, were the key components of a successful initiation protocol for patients with multiple sclerosis starting therapy on dimethyl fumarate. The new protocol resulted in fewer discontinuations than the standard initiation protocol.
A version of injectable interferon that multiple sclerosis patients can use far less frequently than existing products is proving safe and effective in clinical trials, its manufacturer says. Biogen Idec announced that new data from the second year of its Phase III clinical trial of peginterferon beta-1a (Plegridy) show it is well tolerated and appears to halt symptoms of relapsing forms of MS. Patients getting the drug had a lower risk of relapse, less disability progression, and fewer new brain lesions than those who got a placebo.
Altering the Optics of Cardiovascular Disease: How the CANTOS Findings are Changing Physicians' Approach to CVD
Replication of 'Marshmallow Test' Reveals Delayed Gratification May Be Less Predictive of Later Outcomes